Tag Archives: Eli Lilly

Amyvid (Florbetapir 18F) Solution for Injection Recommended for Approval in Europe as a Diagnostic Tool for Imaging Beta-Amyloid Plaques – a Common Neuropathological Feature of Alzheimer’s Disease

– Milestone reflects Eli Lilly and Company’s commitment to bring new diagnostic tool to physicians evaluating patients’ cognitive decline

INDIANAPOLIS, Oct. 19, 2012 /PRNewswire — Eli Lilly and Company (NYSE: